MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.90
-1.13
-4.91%
After Hours: 21.90 0 0.00% 16:08 02/27 EST
OPEN
22.61
PREV CLOSE
23.03
HIGH
23.04
LOW
21.00
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
35.81
52 WEEK LOW
14.62
MARKET CAP
690.18M
P/E (TTM)
-15.9749
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XENT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XENT stock price target is 27.43 with a high estimate of 30.00 and a low estimate of 23.00.

EPS

XENT News

More
  • Intersect ENT (XENT) CEO Tom West on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 3d ago
  • Intersect ENT (XENT) Reports Q4 Loss, Tops Revenue Estimates
  • Zacks · 3d ago
  • Intersect ENT ; Raises FY2020 Sales Guidance from $115M-119M to $115M-119M
  • Benzinga · 3d ago
  • Intersect ENT Q4 EPS $(0.25) Beats $(0.35) Estimate, Sales $31.754M Beat $31.24M Estimate
  • Benzinga · 3d ago

Industry

Medical Equipment, Supplies & Distribution
-2.48%
Healthcare Equipment & Supplies
-2.75%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About XENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
More

Webull offers kinds of Intersect ENT Inc stock information, including NASDAQ:XENT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENT stock news, and many more online research tools to help you make informed decisions.